CLAIMS

1. A process for producing a stable, injectable solution containing from 0.04 to 0.20 mg/ml noradrenaline, characterised by including the following steps:

a. dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, to obtain a concentration of noradrenaline from 0.04 to 0.20 mg/ml,

b. adjusting the pH of the resulting solution by adding hydrochloric acid until a value in the range from 3.2 to 3.6 is achieved,

c. filtrating the resulting noradrenaline solution in an inert gas current,

d. distributing the noradrenaline solution in an inert gas current,

e. sterilizing the noradrenaline solution.

2. A process in accordance with claim 1 wherein the deoxygenated or degassed water is obtained by blowing or bubbling an inert gas current.

3. A process in accordance with claim 2 wherein the water deoxygenated by blowing or bubbling an inert gas current has an oxygen content below 100 ppb.

4. A process according to any one of claims 1-3, wherein said inert gas is selected from nitrogen, argon or a mixture thereof.

5. A process according to any one of claims 1-4, wherein in step b) the pH value is in the range of 3.3 to 3.6.

6. A process according to any one of claims 1-5, wherein the excipient dissolved in step a) is sodium chloride.

7. A process according to any one of claims 1-6, wherein step a) comprises stirring the noradrenaline solution in a nitrogen current.

8. A process according to any one of claims 1-7, wherein the sterilization step e) is carried out under heating.

9. A stable injectable noradrenaline solution with an amount of preservatives and/or anti-oxidizing agents lower than 0.005% by weight, wherein solvent is degassed or deaerated water, the concentration of noradrenaline is in the range from 0.04 to 0.2 mg/ml and pH is from 3.2 to 3.6 by hydrochloric acid.

10. A stable injectable noradrenaline solution according to claim 9, wherein the pH value is in the range of 3.3 to 3.6.

11. A stable injectable noradrenaline solution according to claim 9 or 10, obtained by a process according to any one of claims 1-8.

12. A stable injectable noradrenaline solution in accordance with any one of claims 9-11 further comprising an excipient.

13. A noradrenaline stable injectable solution according to claim 12, wherein the excipient is sodium chloride.

14. A stable injectable noradrenaline solution in accordance with any one of claims 9-13, with an oxygen content equal to or lower than 100 ppb.

15. A stable injectable noradrenaline solution in accordance with any one of claims 9-13, which is free of anti-oxidizing and/or preservative agents.

16. A stable injectable noradrenaline solution according to any one of claims 9-15, for use in the treatment of cardiac circulatory collapse, in states of shock associated with low peripheral resistances or to restore and/or keep physiological pressure levels.

17. Use of a stable injectable noradrenaline solution according to any one of claims 9-15 in the manufacture of a medicament for the treatment of cardiac circulatory collapse, in states of shock associated with low peripheral resistances or to restore and/or keep physiological pressure levels.